SCHEMBL18170915

SCHEMBL18170915

COc1cccc(-c2ccc(NC(=O)c3ccc(NCCCN4CCCCC4)cc3)c3c2CNC3=O)c1OC

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 4/20 0.43
KCNH2 Q12809 4/20 0.43
CHRNA1 P02708 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
KDR P35968 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HTR3A P46098 1/20 0.41
DRD2 P14416 3/20 0.39
DRD4 P21917 3/20 0.39
DRD3 P35462 3/20 0.39
MCHR1 Q99705 3/20 0.39
CHEK1 O14757 1/20 0.38
ACP1 P24666 1/20 0.38
MCHR2 Q969V1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18170606 0.99 KDR (0.42) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL18170843 0.95 KDR (0.43) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL18171034 0.95 KDR (0.43) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL18170829 0.95 KDR (0.43) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL18170856 0.94 KDR (0.42) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL18170861 0.94 KDR (0.43) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL18170521 0.93 HTR3A (0.46) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL18170625 0.93 CHRNA7 (0.45) CHRNA7KCNH2CYP3A4CYP2D6KDR
SCHEMBL18170675 0.93 SMN1; SMN2 (0.46) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL18170640 0.90 KDR (0.43) KDRSMN1; SMN2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US claimed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US claimed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TNIK, TNK1, NFKBIA CHRNA7 2197/4885KCNH2 2704/4885CHRNA1 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.